^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HLX60

    i
    Other names: HLX60
    Associations

    News

    Trials
    Company:
    Fosun Pharma
    Drug class:
    LRRC32 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Hetronifly (serplulimab) • HLX60
    7ms
    A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Aug 2024
    Enrollment closed • Trial primary completion date • Metastases
    |
    HLX60
    over1year
    A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting | N=11 --> 20 | Trial completion date: May 2024 --> Feb 2025 | Trial primary completion date: Sep 2023 --> Feb 2024
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression
    |
    Hetronifly (serplulimab) • HLX60
    over2years
    A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=11, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression
    |
    Hetronifly (serplulimab) • HLX60